Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
LY2109761
i
Other names:
LY2109761
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Eli Lilly
Drug class:
TGF-β R2 kinase inhibitor, TGF-β RI kinase inhibitor
Related drugs:
‹
SHR-1701 (6)
INCA33890 (0)
TST005 (0)
TEW-7197 (1)
ASKC852 (0)
GFH018 (0)
LY3200882 (0)
TP-6379 (0)
SHR-1701 (6)
INCA33890 (0)
TST005 (0)
TEW-7197 (1)
ASKC852 (0)
GFH018 (0)
LY3200882 (0)
TP-6379 (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
PRDX1 overexpression
Hepatocellular Cancer
PRDX1 overexpression
Hepatocellular Cancer
LY2109761
Sensitive: C3 – Early Trials
LY2109761
Sensitive
:
C3
LY2109761
Sensitive: C3 – Early Trials
LY2109761
Sensitive
:
C3
NSD3 overexpression
Breast Cancer
NSD3 overexpression
Breast Cancer
LY2109761
Sensitive: D – Preclinical
LY2109761
Sensitive
:
D
LY2109761
Sensitive: D – Preclinical
LY2109761
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login